Podcast
HemaSphere Podcast
Hosted by HemaSphere Journal · EN
HemaSphere is the official online, open access journal of the European Hematology Association (EHA). HemaSphere publishes exciting basic, translational, and clinical research in hematology. We are pleased to introduce our new podcast series where our host and guest speakers exchange ideas about select HemaSphere publications. Spend some time with us and enjoy casual and insightful discussions about hematology research. Listen to the stories behind the papers. HemaSphere is always accessible; our full range of open access publications is available at www.hemaspherejournal.com.
22episodes
Episodes
Newest firstAll episodes
Why Inflammatory Signaling Holds the Key to Durable MDS Therapies - Dr Manja Wobus, Dr Katja Sockel
2w ago00:38:29Tap to summarizeIn this episode, host Dr Charles de Bock delves into groundbreaking preclinical research exploring the potential of tasquinimod to restore blood cell production and modify the bone marrow microenvironment in MDS with Dr Manja Wobus and Dr Katja Sockel. Join us as we unpack the mechanisms, animal studies, and future clinical prospects for this promising therapy.Read the accompanying article published in HemaSphere https://bit.ly/3OjuuiSi4MDS, EHA's Specialized Working Group information https://hsphere.pub/5d4
Transcribe →p53 in Cancer: Dual Threat - Dr Isabelle Plo, Dr Barbara Monte-Mór
May 700:36:46Tap to summarizeDiscover the latest insights into the multifaceted role of p53 in normal hematopoiesis and its critical involvement in myeloproliferative neoplasms (MPNs). This episode features Dr. Isabelle Plo and Dr. Barbara Monte-Mór sharing their expertise on TP53 mutations, molecular mechanisms driving leukemic transformation, and emerging therapeutic strategies targeting p53.Article: https://bit.ly/4sZbo01Comments, Suggestions or Feedback? Please take a few minutes and let us know: https://wkf.ms/4pDYjYb
Transcribe →Blinatumomab in De Novo AYA ALL - Dr Matthew Greenwood
Feb 900:46:58Tap to summarizeIn this episode, host HemaSphere Scientific Editor Dr Charley de Bock speaks with Associate Professor Dr Matthew Greenwood about the SUBLIME (ALL09) trial, which explores replacing consolidation chemotherapy with blinatumomab in adolescents and young adults with B‑cell ALL. They discuss why immunotherapy may outperform traditional cytotoxic approaches, how MRD‑guided treatment is reshaping risk stratification, and what future protocols might look like as genomic and immune‑response data are integrated in real time. Dr. Greenwood also shares upcoming innovations—including menin inhibitors, venetoclax‑based MRD targeting, and adaptive platform designs—along with honest insights into the challenges of running clinical trials across Australia.
Transcribe →Inequalities in sickle cell therapies - Dr Stephen Hibbs, Dr Paul Telfer, Mary-Shaniqua - Patient Advocate
Dec 200:55:14Tap to summarizeIn this extended episode of the HemaSphere podcast, based on a must-read Perspective "Can health inequalities in sickle cell disease be addressed through novel therapies?", our host Scientific Editor Charles de Bock discusses sickle cell disease with co-authors, covering both expert and lived-patient perspectives. They explore the complexities of living with the disease, the current treatment landscape, and highlight the ongoing health inequalities faced by patients, the impact of withdrawn therapies, and the need for improved communication and trust between patients and healthcare providers.Further information:No One's Listening ReportShaniqua's Sickle ChroniclesNICE (National Institute for Health and Care Excellence)UK NHS blood donationPlease take a few minutes and let us know what you think about this episode! Podcast Feedback
Transcribe →Defining Lineage in Ambiguous Leukemia: A Transcriptomic View - Dr. Anikó Sijs-Szabó & Roger Mulet Lázaro, PhD
Nov 300:35:42Tap to summarizeDr. Anikó Sijs-Szabó & Roger Mulet Lázaro, PhD, join Dr. Charles de Bock to unpack the challenges of diagnosing and treating acute leukemias of ambiguous lineage (ALAL). Discover how RNA sequencing, machine learning, and collaboration are shaping the future of precision medicine in hematology. 🎧 Listen and then read the full open-access article on the HemaSphere website https://bit.ly/4oeJo6w
Transcribe →EHA/EBMT Survey on Grading and Management of ICAHT - Dr Kai Rejeski
Oct 100:40:58Tap to summarizeJoin our host HemaSphere Scientific Editor Dr Charles de Bock as he chats with Dr Kai Rejeski, first author of this 2025 HemaSphere Top Cited –Clinical Award-winning paper. The conversation delves into the complexities of CAR-T therapy, particularly focusing on the associated toxicities and the need for a structured grading system.EHA/EBMT Survey on Grading and Management of ICAHT, is on our website and all major podcast platforms (Spotify, Apple Podcast, and more) and YouTube. Listen and enjoy casual, insightful discussions about #hematology research.You can find the referenced article, in full and open access, here on the HemaSphere website.
Transcribe →Tackling NUP98 Rearranged AML in Pediatric Oncology - Prof Michel Zwaan, Prof Olaf Heidenreich
Sep 100:41:07Tap to summarizeHost Dr Charles de Bock speaks with Prof Michel Zwaan and Prof Olaf Heidenreich, co-authors from the 2025 HemaSphere Award - Top Cited: Biology paper, "The MLL-Menin Interaction is a Therapeutic Vulnerability in NUP98-rearranged AML." The conversation delves into the complexities of #AML, particularly focusing on NUP98 rearranged AML and the therapeutic potential of Menin inhibitors. The discussion highlights the challenges in treating this aggressive form of leukemia, the mechanisms of menin inhibitors, and the importance of combining therapies to improve patient outcomes. Season 3, Episode 5: Tackling NUP98 Rearranged AML in Pediatric Oncology, is on our website and all major podcast platforms. Listen and enjoy casual, insightful discussions about #hematology research.
Transcribe →Part 2 - Metabolism in hematology - Ep 3.4
Jul 2900:28:52Tap to summarizeIn this second part of a 2-part episode, Dr Charles De Bock engages with Prof Dr Petya Apostolova and Dr Jörg Büscher to explore the intricate relationship between metabolism and hematology, particularly focusing on #AML. They discuss the challenges and advancements in metabolomics, the importance of integrating multi-omics approaches, and the future directions of research in this field. The conversation highlights the need for a deeper understanding of metabolic pathways and their implications for cancer treatment, emphasizing the significance of context in cellular behavior and the potential of spatial metabolomics."Metabolism in hematology, Part 2”, is on our website, all major podcast platforms, and YouTube. Listen and enjoy casual, insightful discussions about #hematology research. You can find the referenced Review article, in full and open access, here on the HemaSphere website.
Transcribe →Part 1 - Metabolism in hematology - Ep 3.4
Jul 2900:29:51Tap to summarizeIn this 2-part episode of the HemaSphere podcast, host Dr Charles de Bock and guests Dr Jörg Büscher and Prof Dr Petya Apostolova discuss the critical role of metabolism in cellular function, particularly in the context of hematology and cancer research. The discussion highlights the technological advancements in metabolic analysis and their impact on understanding cellular metabolism. They also explore the challenges and future directions in metabolism research and the potential of spatial metabolomics."Metabolism in hematology”, is on our website, all major podcast platforms, and YouTube. Listen and enjoy casual, insightful discussions about #hematology research. You can find the referenced Review article, in full and open access, here on the HemaSphere website.
Transcribe →Machine learning for AML-MRD - Ep 3.3
Jul 200:29:24Tap to summarizeIn this episode of the HemaSphere podcast, host Charles de Bock and guest Tim Mocking, PhD, discuss the role of machine learning in the assessment of measurable residual disease (MRD) in acute myeloid leukemia (AML). They explore the challenges of MRD detection, the potential of machine learning to improve accuracy and efficiency, and the importance of understanding the human element in computational methods. The conversation also touches on the adoption of AI in hematology, the future of flow cytometry, and the implications of new technologies for patient care.Episode 3.3 - Machine learning for AML-MRD is based on the recently published Review Article "Applications of machine learning for immunophenotypic measurable residual disease assessment in acute myeloid leukemia”, is on our website, all major podcast platforms, and YouTube. Listen and enjoy casual, insightful discussions about #hematology research. You can find the referenced article, in full and open access, here on the HemaSphere website.
Transcribe →